In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck invests in NGM, gets options to license new biologics

Executive Summary

Merck & Co. Inc. paid $94mm up front and $106mm for a 15% equity stake in NGM Biopharmaceuticals Inc., in exchange for the chance to further develop and sell the private biotech’s preclinical biologic therapies for multiple indications.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Includes Contract
    • Co-Promotion
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register